TP53 and hematopoietic and lymphoid cell neoplasm: While seminal studies indicated that CH with TP53 mutations is associated with an increased risk of hematologic malignancy [21, 22], a more recent large‐scale cohort study has challenged this notion, showing that neither TP53 nor PPM1D mutations necessarily increase the risk of hematologic cancer—although this study was conducted in a noncancer patient cohort [23].